Real-world data show endoscopic sleeve gastroplasty is safe and leads to significant and sustained weight loss, even in patients with class III obesity.
"Even those who had regained some slight weight still had 18% weight loss after on average, 4.5 years, with a standard commercial weight management program." No one took antiobesity drugs or had surgery.
Final data from SURMOUNT-3 (tirzepatide), real-world experience with the latest antiobesity drugs, a standards-of-care document in the works, and more will be featured at Obesity Week 2023 in Dallas.